Overview

Study to Evaluate The Safety and Efficacy of Balovaptan in Participants With Acute Ischemic Stroke at High Risk of Developing Malignant Brain Edema

Status:
Not yet recruiting
Trial end date:
2024-06-27
Target enrollment:
Participant gender:
Summary
This study is designed to evaluate the safety, efficacy, and pharmacokinetics of balovaptan compared with placebo in participants with acute ischemic stroke (AIS) at risk of developing Malignant Cerebral Edema (MCE)
Phase:
Phase 2
Details
Lead Sponsor:
Hoffmann-La Roche